These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8090772)

  • 1. Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease.
    Kordower JH; Charles V; Bayer R; Bartus RT; Putney S; Walus LR; Friden PM
    Proc Natl Acad Sci U S A; 1994 Sep; 91(19):9077-80. PubMed ID: 8090772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease.
    Hughes PE; Alexi T; Williams CE; Clark RG; Gluckman PD
    Neuroscience; 1999; 92(1):197-209. PubMed ID: 10392842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular delivery of CNTF but not NT-4/5 prevents degeneration of striatal neurons in a rodent model of Huntington's disease.
    Emerich DF; Bruhn S; Chu Y; Kordower JH
    Cell Transplant; 1998; 7(2):213-25. PubMed ID: 9588602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NGF and anti-transferrin receptor antibody conjugate: short and long-term effects on survival of cholinergic neurons in intraocular septal transplants.
    Granholm AC; Bäckman C; Bloom F; Ebendal T; Gerhardt GA; Hoffer B; Mackerlova L; Olson L; Söderström S; Walus LR
    J Pharmacol Exp Ther; 1994 Jan; 268(1):448-59. PubMed ID: 8301587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA.
    Venero JL; Beck KD; Hefti F
    Neuroscience; 1994 Jul; 61(2):257-68. PubMed ID: 7969907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrophy of cholinergic basal forebrain neurons following excitotoxic cortical lesions is reversed by intravenous administration of an NGF conjugate.
    Charles V; Mufson EJ; Friden PM; Bartus RT; Kordower JH
    Brain Res; 1996 Jul; 728(2):193-203. PubMed ID: 8864482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of transferrin receptor antibody-NGF conjugate on young and aged septal transplants in oculo.
    Bäckman C; Biddle PT; Ebendal T; Friden PM; Gerhardt GA; Henry MA; Mackerlova L; Söderström S; Strömberg I; Walus L
    Exp Neurol; 1995 Mar; 132(1):1-15. PubMed ID: 7720818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease.
    Emerich DF; Winn SR; Hantraye PM; Peschanski M; Chen EY; Chu Y; McDermott P; Baetge EE; Kordower JH
    Nature; 1997 Mar; 386(6623):395-9. PubMed ID: 9121555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease.
    Kells AP; Fong DM; Dragunow M; During MJ; Young D; Connor B
    Mol Ther; 2004 May; 9(5):682-8. PubMed ID: 15120329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats.
    Figueredo-Cardenas G; Anderson KD; Chen Q; Veenman CL; Reiner A
    Exp Neurol; 1994 Sep; 129(1):37-56. PubMed ID: 7925841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease.
    Anderson KD; Panayotatos N; Corcoran TL; Lindsay RM; Wiegand SJ
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7346-51. PubMed ID: 8692996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy.
    Bäckman C; Rose GM; Hoffer BJ; Henry MA; Bartus RT; Friden P; Granholm AC
    J Neurosci; 1996 Sep; 16(17):5437-42. PubMed ID: 8757256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage.
    Menei P; Pean JM; Nerrière-Daguin V; Jollivet C; Brachet P; Benoit JP
    Exp Neurol; 2000 Jan; 161(1):259-72. PubMed ID: 10683292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
    Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
    Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trophic effect of exogenous nerve growth factor on rat striatal cholinergic neurons: comparison between intraparenchymal and intraventricular administration.
    Venero JL; Hefti F; Knusel B
    Mol Pharmacol; 1996 Feb; 49(2):303-10. PubMed ID: 8632763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carrier mediated delivery of NGF: alterations in basal forebrain neurons in aged rats revealed using antibodies against low and high affinity NGF receptors.
    Bäckman C; Rose GM; Bartus RT; Hoffer BJ; Mufson EJ; Granholm AC
    J Comp Neurol; 1997 Oct; 387(1):1-11. PubMed ID: 9331167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A non-invasive system for delivering neural growth factors across the blood-brain barrier: a review.
    Granholm AC; Albeck D; Bäckman C; Curtis M; Ebendal T; Friden P; Henry M; Hoffer B; Kordower J; Rose GM; Söderström S; Bartus RT
    Rev Neurosci; 1998; 9(1):31-55. PubMed ID: 9683326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplants of encapsulated rat choroid plexus cells exert neuroprotection in a rodent model of Huntington's disease.
    Borlongan CV; Thanos CG; Skinner SJ; Geaney M; Emerich DF
    Cell Transplant; 2008; 16(10):987-92. PubMed ID: 18351014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurones.
    Davies SW; Beardsall K
    Neurosci Lett; 1992 Jun; 140(2):161-4. PubMed ID: 1386916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease.
    Emerich DF; Lindner MD; Winn SR; Chen EY; Frydel BR; Kordower JH
    J Neurosci; 1996 Aug; 16(16):5168-81. PubMed ID: 8756445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.